Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Sep 03, 2021 3:09pm
160 Views
Post# 33810376

RE:RE:RE:RE:Medical Advisor Endocrinology United States

RE:RE:RE:RE:Medical Advisor Endocrinology United StatesThere is a market for HIV patients having both lipodystrophy and NAFLD/NASH. After Grinspoon's results we thought Thera would be able to get more patients with both conditions, but it did not materialized. So maybe this new position is an effort to educate HIV doctors with patients having lipo/NAFLD at the same time. These patients would have insurance because they have lipo, both could benefit from Egrifta for NAFLD/NASH at the same time.

Wino115 wrote: I had the same thought as you. I just can't imagine there will be many doctors who will use it like Grinspoon has for his patients. The cost, whether insurance will cover you for NAFLD use, not on label, scientific lit on the light side, etc..  It seems like a longshot.  I guess to cover salary and expenses you'd need a dozen or so prescriptions a year added for NAFLD. Can't really be worth bothering with unless you think you can get hundreds of new patients on it.


<< Previous
Bullboard Posts
Next >>